Insider Transactions in Q1 2023 at Perrigo CO PLC (PRGO)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 13
2023
|
Thomas Farrington EVP and CIO |
SELL
Open market or private sale
|
Direct |
3,723
-30.22%
|
$130,305
$35.58 P/Share
|
|
Mar 10
2023
|
James E Dillard Iii EVP & President CSCA |
SELL
Open market or private sale
|
Direct |
9,000
-26.37%
|
$315,000
$35.7 P/Share
|
|
Mar 08
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Open market or private sale
|
Direct |
4,500
-18.23%
|
$162,000
$36.92 P/Share
|
|
Mar 07
2023
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
510
-6.22%
|
$18,870
$37.71 P/Share
|
|
Mar 07
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,746
+17.55%
|
$64,602
$37.71 P/Share
|
|
Mar 07
2023
|
James E Dillard Iii EVP & President CSCA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,498
-6.82%
|
$92,426
$37.71 P/Share
|
|
Mar 07
2023
|
James E Dillard Iii EVP & President CSCA |
BUY
Exercise of conversion of derivative security
|
Direct |
5,537
+13.13%
|
$204,869
$37.71 P/Share
|
|
Mar 07
2023
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-7.68%
|
$43,290
$37.71 P/Share
|
|
Mar 07
2023
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+12.87%
|
$83,250
$37.71 P/Share
|
|
Mar 07
2023
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-7.66%
|
$41,625
$37.71 P/Share
|
|
Mar 07
2023
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+12.84%
|
$80,031
$37.71 P/Share
|
|
Mar 07
2023
|
Murray S Kessler CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,850
-5.59%
|
$438,450
$37.71 P/Share
|
|
Mar 07
2023
|
Murray S Kessler CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,994
+11.29%
|
$998,778
$37.71 P/Share
|
|
Mar 07
2023
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
5,468
+7.67%
|
$202,316
$37.71 P/Share
|
|
Mar 07
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,099
-4.26%
|
$40,663
$37.71 P/Share
|
|
Mar 07
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,942
+10.24%
|
$108,854
$37.71 P/Share
|
|
Mar 07
2023
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,159
-15.04%
|
$42,883
$37.71 P/Share
|
|
Mar 07
2023
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+23.8%
|
$89,022
$37.71 P/Share
|
|
Mar 06
2023
|
Geoffrey M. Parker Director |
BUY
Open market or private purchase
|
Indirect |
5,000
+23.95%
|
$190,000
$38.05 P/Share
|
|
Mar 03
2023
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,148
-22.51%
|
$157,624
$38.75 P/Share
|
|
Mar 03
2023
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,954
+21.36%
|
$112,252
$38.75 P/Share
|
|
Mar 03
2023
|
Thomas Farrington EVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
6,493
+50.0%
|
$246,734
$38.75 P/Share
|
|
Mar 03
2023
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
5,951
+4.81%
|
$226,138
$38.75 P/Share
|
|
Mar 03
2023
|
Svend Andersen EVP & President CHCI |
BUY
Grant, award, or other acquisition
|
Direct |
13,081
+19.38%
|
$497,078
$38.75 P/Share
|
|
Mar 03
2023
|
James E Dillard Iii EVP & President CSCA |
SELL
Payment of exercise price or tax liability
|
Direct |
6,799
-6.94%
|
$258,362
$38.75 P/Share
|
|
Mar 03
2023
|
James E Dillard Iii EVP & President CSCA |
BUY
Exercise of conversion of derivative security
|
Direct |
4,675
+6.9%
|
$177,650
$38.75 P/Share
|
|
Mar 03
2023
|
James E Dillard Iii EVP & President CSCA |
BUY
Grant, award, or other acquisition
|
Direct |
10,277
+23.63%
|
$390,526
$38.75 P/Share
|
|
Mar 03
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,392
-6.25%
|
$166,896
$38.75 P/Share
|
|
Mar 03
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,613
+7.29%
|
$137,294
$38.75 P/Share
|
|
Mar 03
2023
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
7,941
+25.16%
|
$301,758
$38.75 P/Share
|
|
Mar 03
2023
|
Murray S Kessler CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
40,685
-7.11%
|
$1,546,030
$38.75 P/Share
|
|
Mar 03
2023
|
Murray S Kessler CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,944
+8.13%
|
$1,251,872
$38.75 P/Share
|
|
Mar 03
2023
|
Murray S Kessler CEO |
BUY
Grant, award, or other acquisition
|
Direct |
72,410
+27.29%
|
$2,751,580
$38.75 P/Share
|
|
Mar 03
2023
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,186
-6.32%
|
$45,068
$38.75 P/Share
|
|
Mar 03
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,208
+13.81%
|
$83,904
$38.75 P/Share
|
|
Mar 03
2023
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
677
+11.08%
|
$25,726
$38.75 P/Share
|
|
Mar 03
2023
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,713
-9.09%
|
$141,094
$38.75 P/Share
|
|
Mar 03
2023
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,231
+7.99%
|
$84,778
$38.75 P/Share
|
|
Mar 03
2023
|
Robert Willis EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
4,905
+25.95%
|
$186,390
$38.75 P/Share
|
|
Mar 03
2023
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,190
-9.88%
|
$159,220
$38.75 P/Share
|
|
Mar 03
2023
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,636
+8.95%
|
$100,168
$38.75 P/Share
|
|
Mar 03
2023
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,419
+27.15%
|
$205,922
$38.75 P/Share
|